Open access · CC-BY
via OpenAlex
Cell type specific contributions of mTOR inhibition that drive neuroprotective mechanisms in Alzheimer’s disease
Kathryn A. Haynes, Diogo Francisco da Silva dos Santos, Sean‐Paul Gerard Williams, Jason T Hart, Alicia M Lehman, Seana E Eckels, Umesh Nepali, Aman Reddy, Toren Finkel, Stacey J. Sukoff Rizzo
Alzheimer s & Dementia · 2024
Deregulated nutrient-sensing
Altered intercellular communication
Chronic inflammation
Disabled macroautophagy
Rapamycin / mTOR inhibition
Human
Mouse
Preclinical / animal
Abstract
Abstract Background Studies investigating mTOR(definition) signaling provide compelling and reproducible evidence of the extension of lifespan across model organisms by treatment with the mTOR inhibitor rapamycin(definition), and preclinical data suggests neuroprotective benefits of rapamycin in models of Alzheimer’s disease (AD). Rapamycin has potent immunosuppressive and autophagy(definition) activating effects though it remains unknown whether rapamycin’s neuroprotective and lifespan enhancing effects are achieved through modulating systemic inflammation, augmenting autophagy, or via some combination of modifying both these factors. Relatedly, the cellular and molecular mechanisms that contribute to rapamycin’s neuroprotective effects in AD remain unclear. The purpose of these studies is to identify the brain‐specific cell types that contribute to the protective effects of mTOR inhibition in progressive AD. Method For these studies we crossed a transgenic mouse model of familial early onset amyloid plaque deposition (5XFAD; JAX#034848) with a mouse genetically engineered with reduced mTOR expression to ∼25% of WT levels (mTORΔ/Δ). Previous studies have demonstrated that these mTOR hypomorph mice exhibit a 20% extension in lifespan. We then generated chimeric mice by crossing mTORΔ/Δ/5XFAD carriers to neuronal‐, microglial‐, and astrocyte‐specific Cre+ lines, resulting in mTOR expression reduced to 25% of WT except in the specific Cre+ cell type. Male and female subjects were evaluated longitudinally across the lifespan for measures of healthspan(definition) using a frailty assessment and compared to WT littermate controls. Result Offspring from all crosses of mTORΔ/Δ; 5xFAD; and neuronal (Syn1‐cre; JAX#003966), astroglial (Gfap‐cre; JAX#012896) or microglial (Cx3cr1‐cre; JAX#025524) cre‐expressing mice were viable with cohorts bred to N = 10/sex/genotype/cre line for longitudinal lifespan and healthspan assessments. Evaluation of frailty scores assessed at 12 months of age reveal the expected increase in frailty in 5XFAD relative to WT littermate controls with reduced frailty scores in mTORΔ/Δ carrier mice including mTORΔ/Δ/5XFAD crosses. Conclusion The present interim results confirm and extend the protective effects of ubiquitous reduction of mTOR expression. Ongoing studies in Cre+ lines will determine in which cell types reduced mTOR signaling is necessary for neuroprotection by comprehensive characterization of these models in functional assessments, AD biomarkers and relevant pathology.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1002/alz.092635
- Canonical
- link ↗
- Fetched
- 2026-10-07 MST
Cite this
APA
Haynes, K.A., Santos, D.F.D.S.D., Williams, S.G., Hart, J.T., Lehman, A.M., Eckels, S.E., Nepali, U., Reddy, A., Finkel, T., & Rizzo, S.J.S. (2024). Cell type specific contributions of mTOR inhibition that drive neuroprotective mechanisms in Alzheimer’s disease. <em>Alzheimer s & Dementia</em>. https://doi.org/10.1002/alz.092635
Vancouver
Haynes KA, Santos DFDSD, Williams SG, Hart JT, Lehman AM, Eckels SE, et al. Cell type specific contributions of mTOR inhibition that drive neuroprotective mechanisms in Alzheimer’s disease. Alzheimer s & Dementia. 2024. doi:10.1002/alz.092635.
BibTeX
@article{kathryn2024Cellty,
title = {Cell type specific contributions of mTOR inhibition that drive neuroprotective mechanisms in Alzheimer’s disease},
author = {Kathryn A. Haynes and Diogo Francisco da Silva dos Santos and Sean‐Paul Gerard Williams and Jason T Hart and Alicia M Lehman and Seana E Eckels and Umesh Nepali and Aman Reddy and Toren Finkel and Stacey J. Sukoff Rizzo},
journal = {Alzheimer s & Dementia},
year = {2024},
doi = {10.1002/alz.092635},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Cell Cycle 2011
Open access · OA
From growing to secreting: New roles for mTOR in aging cells
EXCLI journal 2019
Open access · CC-BY
The mTOR kinase inhibitor rapamycin enhances the expression and release of pro-inflammatory cytokine interleukin 6 modulating the activation of human microglial cells
Aging Cell 2015
Open access · CC-BY
Chronic mTOR inhibition in mice with rapamycin alters T , B , myeloid, and innate lymphoid cells and gut flora and prolongs life of immune‐deficient mice
Cell Cycle 2013
Open access · OA
Chronic rapamycin treatment or lack ofS6K1does not reduce ribosome activity in vivo
Autophagy 2023
Preprint · OA
Rapamycin and Alzheimer disease: a hypothesis for the effective use of rapamycin for treatment of neurodegenerative disease
Acta Ophthalmologica 2018
Open access · OA